Switch theme
Sign up to access all valuation multiples
J.B. Chemicals & Pharmaceuticals Ltd is an India-based pharmaceutical company. It manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs). The company's products include various pharmaceutical dosage forms like tablets, injectable, creams, ointments, lozenges, herbal liquids, and capsules. It also offers services including optimization of formulations, scale-up services, stability testing, regulatory support, packaging design, and commercial production. The group derives revenue from the manufacturing and marketing of a diverse range of pharmaceutical products. The company sells its products in India and also exports them to other international countries.
1976
5.5K+
LTM Revenue $468M
LTM EBITDA $126M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
J.B. Chemicals & Pharma has a last 12-month revenue (LTM) of $468M and a last 12-month EBITDA of $126M.
In the most recent fiscal year, J.B. Chemicals & Pharma achieved revenue of $441M and an EBITDA of $122M.
J.B. Chemicals & Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See J.B. Chemicals & Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $468M | XXX | $441M | XXX | XXX | XXX |
| Gross Profit | $311M | XXX | $288M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $126M | XXX | $122M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $106M | XXX | $97.7M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $81.9M | XXX | $75.4M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, J.B. Chemicals & Pharma's stock price is INR 1714 (or $20).
J.B. Chemicals & Pharma has current market cap of INR 268B (or $3.1B), and EV of INR 264B (or $3.0B).
See J.B. Chemicals & Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.1B | XXX | XXX | XXX | XXX | $0.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, J.B. Chemicals & Pharma has market cap of $3.1B and EV of $3.0B.
J.B. Chemicals & Pharma's trades at 7.0x EV/Revenue multiple, and 25.5x EV/EBITDA.
Equity research analysts estimate J.B. Chemicals & Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
J.B. Chemicals & Pharma has a P/E ratio of 37.4x.
See valuation multiples for J.B. Chemicals & Pharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 24.0x | XXX | 25.5x | XXX | XXX | XXX |
| EV/EBIT | 28.5x | XXX | 31.8x | XXX | XXX | XXX |
| EV/Gross Profit | 9.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 37.4x | XXX | 42.4x | XXX | XXX | XXX |
| EV/FCF | 36.9x | XXX | 36.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJ.B. Chemicals & Pharma's last 12 month revenue growth is 12%
J.B. Chemicals & Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $35K for the same period.
J.B. Chemicals & Pharma's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
J.B. Chemicals & Pharma's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for J.B. Chemicals & Pharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
J.B. Chemicals & Pharma acquired XXX companies to date.
Last acquisition by J.B. Chemicals & Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . J.B. Chemicals & Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was J.B. Chemicals & Pharma founded? | J.B. Chemicals & Pharma was founded in 1976. |
| Where is J.B. Chemicals & Pharma headquartered? | J.B. Chemicals & Pharma is headquartered in India. |
| How many employees does J.B. Chemicals & Pharma have? | As of today, J.B. Chemicals & Pharma has 5.5K+ employees. |
| Who is the CEO of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's CEO is Mr. Nikhil Ashok kumar Chopra. |
| Is J.B. Chemicals & Pharma publicy listed? | Yes, J.B. Chemicals & Pharma is a public company listed on BOM. |
| What is the stock symbol of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma trades under 506943 ticker. |
| When did J.B. Chemicals & Pharma go public? | J.B. Chemicals & Pharma went public in 1991. |
| Who are competitors of J.B. Chemicals & Pharma? | Similar companies to J.B. Chemicals & Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's current market cap is $3.1B |
| What is the current revenue of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's last 12 months revenue is $468M. |
| What is the current revenue growth of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of J.B. Chemicals & Pharma? | Current revenue multiple of J.B. Chemicals & Pharma is 6.4x. |
| Is J.B. Chemicals & Pharma profitable? | Yes, J.B. Chemicals & Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's last 12 months EBITDA is $126M. |
| What is J.B. Chemicals & Pharma's EBITDA margin? | J.B. Chemicals & Pharma's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of J.B. Chemicals & Pharma? | Current EBITDA multiple of J.B. Chemicals & Pharma is 24.0x. |
| What is the current FCF of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's last 12 months FCF is $81.7M. |
| What is J.B. Chemicals & Pharma's FCF margin? | J.B. Chemicals & Pharma's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of J.B. Chemicals & Pharma? | Current FCF multiple of J.B. Chemicals & Pharma is 36.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
